Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Saint Patrick Hospital - Community Hospital
394
mi
from 98109
Missoula, MT
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Saint Patrick Hospital - Community Hospital
394
mi
from 98109
Missoula, MT
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Nebraska Methodist Hospital
1361
mi
from 98109
Omaha, NE
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Nebraska Methodist Hospital
1361
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Univ of Nebraska Med Ctr
1366
mi
from 98109
Omaha, NE
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Univ of Nebraska Med Ctr
1366
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Cancer and Blood Specialists-Henderson
889
mi
from 98109
Henderson, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Cancer and Blood Specialists-Henderson
889
mi
from 98109
Henderson, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Comprehensive Cancer Centers of Nevada - Henderson
886
mi
from 98109
Henderson, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Comprehensive Cancer Centers of Nevada - Henderson
886
mi
from 98109
Henderson, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Las Vegas Cancer Center-Henderson
889
mi
from 98109
Henderson, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Las Vegas Cancer Center-Henderson
889
mi
from 98109
Henderson, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
21st Century Oncology - Henderson
883
mi
from 98109
Henderson, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
21st Century Oncology - Henderson
883
mi
from 98109
Henderson, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Comprehensive Cancer Centers of Nevada-Southeast Henderson
883
mi
from 98109
Henderson, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Comprehensive Cancer Centers of Nevada-Southeast Henderson
883
mi
from 98109
Henderson, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
University Medical Center of Southern Nevada
873
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
University Medical Center of Southern Nevada
873
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Cancer and Blood Specialists-Shadow
871
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Cancer and Blood Specialists-Shadow
871
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Nevada Cancer Research Foundation CCOP
873
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Nevada Cancer Research Foundation CCOP
873
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Radiation Oncology Centers of Nevada Central
871
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Radiation Oncology Centers of Nevada Central
871
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
21st Century Oncology
875
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
21st Century Oncology
875
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
875
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
875
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
HealthCare Partners Medical Group Oncology/Hematology-San Martin
878
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
HealthCare Partners Medical Group Oncology/Hematology-San Martin
878
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Radiation Oncology Centers of Nevada Southeast
879
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Radiation Oncology Centers of Nevada Southeast
879
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Cancer Therapy and Integrative Medicine
877
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Cancer Therapy and Integrative Medicine
877
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Cancer and Blood Specialists-Tenaya
868
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Cancer and Blood Specialists-Tenaya
868
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Comprehensive Cancer Centers of Nevada - Northwest
868
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Comprehensive Cancer Centers of Nevada - Northwest
868
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
868
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
868
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Comprehensive Cancer Centers of Nevada-Summerlin
869
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Comprehensive Cancer Centers of Nevada-Summerlin
869
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Las Vegas Cancer Center-Medical Center
877
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Las Vegas Cancer Center-Medical Center
877
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
21st Century Oncology - Fort Apache
875
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
21st Century Oncology - Fort Apache
875
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Comprehensive Cancer Centers of Nevada
878
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Comprehensive Cancer Centers of Nevada
878
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
863
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
863
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Comprehensive Cancer Centers of Nevada - Central Valley
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Comprehensive Cancer Centers of Nevada - Central Valley
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
21st Century Oncology - Vegas Tenaya
873
mi
from 98109
Las Vegas, NV
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
21st Century Oncology - Vegas Tenaya
873
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Morristown Medical Center
2377
mi
from 98109
Morristown, NJ
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Morristown Medical Center
2377
mi
from 98109
Morristown, NJ
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Overlook Hospital
2385
mi
from 98109
Summit, NJ
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Overlook Hospital
2385
mi
from 98109
Summit, NJ
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Kinston Medical Specialists
2429
mi
from 98109
Kinston, NC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Kinston Medical Specialists
2429
mi
from 98109
Kinston, NC
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Wake Forest University Health Sciences
2279
mi
from 98109
Winston-Salem, NC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Wake Forest University Health Sciences
2279
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
The Christ Hospital
1966
mi
from 98109
Cincinnati, OH
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
The Christ Hospital
1966
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
University of Oklahoma Health Sciences Center
1524
mi
from 98109
Oklahoma City, OK
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
University of Oklahoma Health Sciences Center
1524
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
1568
mi
from 98109
Tulsa, OK
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
1568
mi
from 98109
Tulsa, OK
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Clackamas Radiation Oncology Center
153
mi
from 98109
Clackamas, OR
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Clackamas Radiation Oncology Center
153
mi
from 98109
Clackamas, OR
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Providence Milwaukie Hospital
151
mi
from 98109
Milwaukie, OR
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Providence Milwaukie Hospital
151
mi
from 98109
Milwaukie, OR
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Providence Newberg Medical Center
163
mi
from 98109
Newberg, OR
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Providence Newberg Medical Center
163
mi
from 98109
Newberg, OR
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Providence Willamette Falls Medical Center
mi
from 98109
Oregon City, OR
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Providence Willamette Falls Medical Center
mi
from 98109
Oregon City, OR
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Providence Portland Medical Center
147
mi
from 98109
Portland, OR
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Providence Portland Medical Center
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Providence Saint Vincent Medical Center
148
mi
from 98109
Portland, OR
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Providence Saint Vincent Medical Center
148
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
University of Pennsylvania:Abramson Cancer Center
2371
mi
from 98109
Philadelphia, PA
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
University of Pennsylvania:Abramson Cancer Center
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Greenville Health System Cancer Institute-Easley
2216
mi
from 98109
Easley, SC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Greenville Health System Cancer Institute-Easley
2216
mi
from 98109
Easley, SC
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Greenville Health System Cancer Institute-Andrews
2224
mi
from 98109
Greenville, SC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Greenville Health System Cancer Institute-Andrews
2224
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Greenville Health System Cancer Institute-Butternut
2229
mi
from 98109
Greenville, SC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Greenville Health System Cancer Institute-Butternut
2229
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Greenville Health System Cancer Institute-Faris
2229
mi
from 98109
Greenville, SC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Greenville Health System Cancer Institute-Faris
2229
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Greenville Memorial Hospital
2227
mi
from 98109
Greenville, SC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Greenville Memorial Hospital
2227
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Greenville Health System Cancer Institute/Eastside
2226
mi
from 98109
Greenville, SC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Greenville Health System Cancer Institute/Eastside
2226
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated:  9/13/2017
Greenville Health System Cancer Institute-Greer
2229
mi
from 98109
Greer, SC
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Status: Enrolling
Updated: 9/13/2017
Greenville Health System Cancer Institute-Greer
2229
mi
from 98109
Greer, SC
Click here to add this to my saved trials